Overview

Our founders discovered that certain short chain fatty acids (SCFAs) had the potential to be used as powerful therapeutic agents for several serious and life-threatening hematologic disorders. They identified novel epigenetic mechanisms of action in which these compounds target the expression of key genes required to generate their therapeutic effects. Several of these SCFA compounds were evaluated in the laboratory as well as relevant pre-clinical animal models. HemaQuest has selected two of these compounds, HQK-1001 and HQK-1004, for clinical development to treat hemoglobin disorders and virally-related cancers, respectively. These two drug candidates are straightforward and inexpensive to manufacture and have demonstrated strong safety profiles both in animal studies as well as clinical studies. They have shown promising pharmacodynamic and therapeutic effects in early stage clinical trials. HemaQuest is currently advancing these compounds in Phase 2 clinical trials, which if successful, could lead to pivotal trials beginning in 2011.

HemaQuest Pipeline